David Kandzari, MD, from the Piedmont Heart Institute, led a group of researchers to assess the cost-effectiveness of renal denervation based on clinical event risk reduction, quality of life measures and projected lifetime costs. Data from the SPYRAL HTN-ON MED study was used for the assessment.
“The cost-effectiveness of [renal denervation] was robust across a broad range of scenarios and sensitivity analyses,” the researchers wrote.
The study found that renal denervation had an incremental cost-effectiveness ratio of $32,732 per quality-adjusted life years. Ratios below $50,000 per quality-adjusted life years are considered to indicate an intervention is cost-effective and has “high value,” according to an Aug. 23 TCTMD report.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
